{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:19:25Z","timestamp":1794932365778,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03535-y","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:46:16Z","timestamp":1788536776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality by Design for Bilayer Tablets: Integrating Formulation, Manufacturing, and Process Analytical Technology"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-0384","authenticated-orcid":false,"given":"Joao D","family":"Sim\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-8944","authenticated-orcid":false,"given":"Ant\u00f3nio J","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3535_CR1","doi-asserted-by":"publisher","unstructured":"Higaki J, Komuro I, Shiki K, Ugai H, Taniguchi A, Ikeda H, et al. The efficacy and long-term safety of a triple combination of 80\u2009mg telmisartan, 5\u2009mg amlodipine and 12.5\u2009mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. Hypertens Res. 2017;40(1):51\u201360.\u00a0https:\/\/doi.org\/10.1038\/hr.2016.100","DOI":"10.1038\/hr.2016.100"},{"key":"3535_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/967073","author":"KA Van Galen","year":"2014","unstructured":"Van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014. https:\/\/doi.org\/10.1155\/2014\/967073.","journal-title":"AIDS Res Treat"},{"issue":"1","key":"3535_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737167.2020.1734456","volume":"20","author":"B Godman","year":"2020","unstructured":"Godman B, McCabe H, Leong TD, Mueller D, Martin AP, Hoxha I, et al. Fixed dose drug combinations \u2013 are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):1\u201326. https:\/\/doi.org\/10.1080\/14737167.2020.1734456.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"3535_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40005-016-0286-4","volume":"46","author":"C Moon","year":"2016","unstructured":"Moon C, Oh E. Rationale and strategies for formulation development of oral fixed dose combination drug products. J Pharm Inv. 2016;46(7):615\u201331. https:\/\/doi.org\/10.1007\/s40005-016-0286-4.","journal-title":"J Pharm Inv"},{"key":"3535_CR5","doi-asserted-by":"publisher","unstructured":"Janczura M, Sip S, Cielecka-Piontek J. The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients. Pharmaceutics. 2022;14(4):834.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics14040834","DOI":"10.3390\/pharmaceutics14040834"},{"key":"3535_CR6","doi-asserted-by":"publisher","unstructured":"Akhtar M, Jamshaid M, Zaman M, Mirza AZ. Bilayer tablets: A developing novel drug delivery system. J Drug Del Sci Technol. 2020;60:102079.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2020.102079","DOI":"10.1016\/j.jddst.2020.102079"},{"key":"3535_CR7","doi-asserted-by":"publisher","unstructured":"Fernandez-Garcia R, Prada M, Bolas-Fernandez F, Ballesteros MP, Serrano DR. Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing. Pharm Res. 2020;37(7):132.\u00a0https:\/\/doi.org\/10.1007\/s11095-020-02847-3","DOI":"10.1007\/s11095-020-02847-3"},{"key":"3535_CR8","first-page":"247","volume-title":"Pharmaceutical dosage forms-tablets","author":"W Gunsel","year":"1989","unstructured":"Gunsel W, Dusel R. Compression-coated and layer tablets. In: Lieberman HALL, Schwartz JB, editors. Pharmaceutical dosage forms-tablets. 1st ed. New York: Marcel Dekker; 1989. p. 247\u201384.","edition":"1"},{"issue":"4","key":"3535_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2478\/cipms-2019-0039","volume":"32","author":"T Blicharski","year":"2019","unstructured":"Blicharski T, Swiader K, Serefko A, Kulczycka-Mamona S, Kolodziejczyk M, Szopa A. Challenges in technology of bilayer and multi-layer tablets: a mini-review. Curr Issues Pharm Med Sci. 2019;32(4):229\u201335. https:\/\/doi.org\/10.2478\/cipms-2019-0039.","journal-title":"Curr Issues Pharm Med Sci"},{"key":"3535_CR10","doi-asserted-by":"publisher","unstructured":"Derington CG, Cohen JB, Bress AP. Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations. J Hum Hypertens. 2020;34(9):617\u201323.\u00a0https:\/\/doi.org\/10.1038\/s41371-020-0340-6","DOI":"10.1038\/s41371-020-0340-6"},{"key":"3535_CR11","doi-asserted-by":"publisher","unstructured":"Bellini M, Walther M, Bodmeier R. Evaluation of manufacturing process parameters causing multilayer tablets delamination. Int J Pharm. 2019;570:118607.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118607","DOI":"10.1016\/j.ijpharm.2019.118607"},{"issue":"9","key":"3535_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091443","volume":"13","author":"M-H Chun","year":"2021","unstructured":"Chun M-H, Kim JY, Park E-S, Choi DH. Development of a robust control strategy for fixed-dose combination bilayer tablets with integrated quality by design, statistical, and process analytical technology approach. Pharmaceutics. 2021;13(9):1443. https:\/\/doi.org\/10.3390\/pharmaceutics13091443.","journal-title":"Pharmaceutics"},{"key":"3535_CR13","unstructured":"Q8 (R2) Guideline: Pharmaceutical Development. 2009.\u00a0https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf (03 May 2025)"},{"key":"3535_CR14","unstructured":"Q9 Guideline: Quality Risk Management. 2005.\u00a0https:\/\/database.ich.org\/sites\/default\/files\/Q9%20Guideline.pdf (03 May 2025)"},{"key":"3535_CR15","unstructured":"Q10 Guideline: Pharmaceutical Quality System 2008.\u00a0https:\/\/database.ich.org\/sites\/default\/files\/Q10%20Guideline.pdf (03 May 2025)"},{"key":"3535_CR16","doi-asserted-by":"publisher","unstructured":"Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance. AAPS J. 2025;27(4):96.\u00a0https:\/\/doi.org\/10.1208\/s12248-025-01079-w","DOI":"10.1208\/s12248-025-01079-w"},{"key":"3535_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060919","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Kim JH, Kim MS, Jeong SH, Choi DH. Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13060919.","journal-title":"Pharmaceutics"},{"key":"3535_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40005-022-00603-w","volume":"53","author":"AS Sousa","year":"2023","unstructured":"Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. A quality by design approach in oral extended release drug delivery systems: where we are and where we are going. J Pharm Investig. 2023;53:269\u2013306. https:\/\/doi.org\/10.1007\/s40005-022-00603-w.","journal-title":"J Pharm Investig"},{"key":"3535_CR19","doi-asserted-by":"publisher","unstructured":"Tome T, \u017digart N, \u010casar Z, Obreza A. Development and Optimization of Liquid Chromatography Analytical Methods by Using AQbD Principles: Overview and Recent Advances. Org Process Res Dev. 2019;23(9):1784\u2013802.\u00a0https:\/\/doi.org\/10.1021\/acs.oprd.9b00238","DOI":"10.1021\/acs.oprd.9b00238"},{"key":"3535_CR20","doi-asserted-by":"publisher","unstructured":"Fukuda IM, Pinto CFF, Moreira CdS, Saviano AM, Louren\u00e7o FR. Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD). Braz J Pharm Sci. 2018;54:1\u201316 art. e01006.\u00a0https:\/\/doi.org\/10.1590\/s2175-97902018000001006","DOI":"10.1590\/s2175-97902018000001006"},{"key":"3535_CR21","doi-asserted-by":"publisher","unstructured":"Verch T, Campa C, Ch\u00e9ry CC, Frenkel R, Graul T, Jaya N, et al. Analytical Quality by Design, Life Cycle Management, and Method Control. AAPS J. 2022;24(1):34.\u00a0https:\/\/doi.org\/10.1208\/s12248-022-00685-2","DOI":"10.1208\/s12248-022-00685-2"},{"key":"3535_CR22","doi-asserted-by":"publisher","unstructured":"Sen S, Ganta B, Rachel VN, Gogikar SK, Singh V, Sonti R, et al. Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review. J Pharm Sci. 2024;113(8):2028\u201343.\u00a0https:\/\/doi.org\/10.1016\/j.xphs.2024.04.025","DOI":"10.1016\/j.xphs.2024.04.025"},{"key":"3535_CR23","doi-asserted-by":"publisher","unstructured":"Prajapati PB, Radadiya K, Shah SA. Quality Risk Management Based: Analytical Quality by Design Approach to Eco-Friendly and Versatile Chromatography Method for Simultaneous Estimation of Multiple Fixed-Dose-Combination Products of Anti-Diabetic Drugs. J Pharm Innov. 2022;17(1):111\u201328.\u00a0https:\/\/doi.org\/10.1007\/s12247-020-09506-5","DOI":"10.1007\/s12247-020-09506-5"},{"issue":"1-2","key":"3535_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ijpharm.2013.12.028","volume":"461","author":"A Abebe","year":"2014","unstructured":"Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. Review of bilayer tablet technology. Int J Pharm. 2014;461(1\u20132):549\u201358. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.12.028.","journal-title":"Int J Pharm"},{"key":"3535_CR25","doi-asserted-by":"publisher","unstructured":"Hwang K-M, Cho C-H, Lee S-H, Kim J-Y, Park E-S. Preformulation and evaluation of multi-layer tablets. J Pharm Inv. 2024;54(2):161\u201374.\u00a0https:\/\/doi.org\/10.1007\/s40005-024-00673-y","DOI":"10.1007\/s40005-024-00673-y"},{"key":"3535_CR26","doi-asserted-by":"publisher","unstructured":"Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. Unveiling Swelling and Erosion Dynamics: Early Development Screening of Mirabegron Extended Release Tablets. AAPS PharmSciTech. 2024;25(8):277.\u00a0https:\/\/doi.org\/10.1208\/s12249-024-02994-5","DOI":"10.1208\/s12249-024-02994-5"},{"key":"3535_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106412","volume":"184","author":"J Sim\u00e3o","year":"2023","unstructured":"Sim\u00e3o J, Chaudhary SA, Ribeiro AJ. Implementation of quality by design (QbD) for development of bilayer tablets. Eur J Pharm Sci. 2023;184:106412. https:\/\/doi.org\/10.1016\/j.ejps.2023.106412.","journal-title":"Eur J Pharm Sci"},{"key":"3535_CR28","doi-asserted-by":"publisher","unstructured":"Burnier M, Egan BM. Adherence in Hypertension A Review of Prevalence, Risk Factors, Impact, and Management. Circ Res. 2019;124(7):1124\u201340.\u00a0https:\/\/doi.org\/10.1161\/circresaha.118.313220","DOI":"10.1161\/circresaha.118.313220"},{"key":"3535_CR29","doi-asserted-by":"publisher","unstructured":"Calcagno A, de Nicolo A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, et al. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. Br J Clin Pharmacol. 2021;47:4432\u2013 8.\u00a0https:\/\/doi.org\/10.1111\/bcp.14869","DOI":"10.1111\/bcp.14869"},{"key":"3535_CR30","doi-asserted-by":"publisher","unstructured":"Ameen MSM, Ibrahim NJ, Omar TA. Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine. J Pharm Innov. 2023;18(3):1213\u201328.\u00a0https:\/\/doi.org\/10.1007\/s12247-022-09694-2","DOI":"10.1007\/s12247-022-09694-2"},{"key":"3535_CR31","doi-asserted-by":"publisher","unstructured":"Kim T-K, Lee J-E, Jeong K, Baek M-J, Kim D, Jeon J-Y, et al. Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension and dyslipidemia. J Pharm Inv. 2024;54(1):99\u2013112.\u00a0https:\/\/doi.org\/10.1007\/s40005-023-00651-w","DOI":"10.1007\/s40005-023-00651-w"},{"key":"3535_CR32","doi-asserted-by":"publisher","unstructured":"Desai D, Wang J, Wen H, Li XH, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265\u201376.\u00a0https:\/\/doi.org\/10.3109\/10837450.2012.660699","DOI":"10.3109\/10837450.2012.660699"},{"key":"3535_CR33","doi-asserted-by":"publisher","unstructured":"Abu Esba LC, Yousef C, Ismail S, Halim M, Almodaimegh H, Al-Abdulkarim HA, et al. Fixed dose combinations: A formulary decision guide. Health Policy Technol. 2021;10(2):100500.\u00a0https:\/\/doi.org\/10.1016\/j.hlpt.2021.02.006","DOI":"10.1016\/j.hlpt.2021.02.006"},{"key":"3535_CR34","doi-asserted-by":"publisher","unstructured":"Chang SY, Sun CC. Interfacial bonding in formulated bilayer tablets. Eur J Pharm Biopharm. 2020;147:69\u201375.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2019.12.009","DOI":"10.1016\/j.ejpb.2019.12.009"},{"key":"3535_CR35","doi-asserted-by":"publisher","unstructured":"Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. Leveraging a multivariate approach towards enhanced development of direct compression extended release tablets. Int J Pharm. 2023;646:123432.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123432","DOI":"10.1016\/j.ijpharm.2023.123432"},{"key":"3535_CR36","doi-asserted-by":"publisher","unstructured":"Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding Pharmaceutical Quality by Design. AAPS J. 2014;16(4):771\u201383.\u00a0https:\/\/doi.org\/10.1208\/s12248-014-9598-3","DOI":"10.1208\/s12248-014-9598-3"},{"key":"3535_CR37","doi-asserted-by":"publisher","unstructured":"Busignies V, Mazel V, Diarra H, Tchoreloff P. Role of the elasticity of pharmaceutical materials on the interfacial mechanical strength of bilayer tablets. Int J Pharm. 2013;457(1):260\u20137.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2013.09.009","DOI":"10.1016\/j.ijpharm.2013.09.009"},{"key":"3535_CR38","doi-asserted-by":"publisher","unstructured":"Papos K, Kasa P, Ilic I, Blatnik-Urek S, Regdon G, Srcic S, et al. Effect of the surface free energy of materials on the lamination tendency of bilayer tablets. Int J Pharm. 2015;496(2):609\u201313. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.10.061","DOI":"10.1016\/j.ijpharm.2015.10.061"},{"issue":"6","key":"3535_CR39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3109\/03639045.2013.788014","volume":"40","author":"BM Zacour","year":"2014","unstructured":"Zacour BM, Pandey P, Subramanian G, Gao JZ, Nikfar F. Correlating bilayer tablet delamination tendencies to micro-environmental thermodynamic conditions during pan coating. Drug Dev Ind Pharm. 2014;40(6):829\u201337. https:\/\/doi.org\/10.3109\/03639045.2013.788014.","journal-title":"Drug Dev Ind Pharm"},{"key":"3535_CR40","doi-asserted-by":"publisher","unstructured":"Jin F, Tatavarti A. Tabletability assessment of conventional formulations containing Vitamin E tocopheryl polyethylene glycol succinate. Int J Pharm. 2010;389(1):58\u201365.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2010.01.017","DOI":"10.1016\/j.ijpharm.2010.01.017"},{"key":"3535_CR41","doi-asserted-by":"publisher","unstructured":"Corredor CC, Vikstrom C, Persson A, Bu X, Both D. Development and Robustness Verification of an At-Line Transmission Raman Method for Pharmaceutical Tablets Using Quality by Design (QbD) Principles. J Pharm Innov. 2018;13(4):287\u2013300.\u00a0https:\/\/doi.org\/10.1007\/s12247-018-9334-0","DOI":"10.1007\/s12247-018-9334-0"},{"key":"3535_CR42","doi-asserted-by":"publisher","unstructured":"Dey S, Mahanti B, Khila S, Mazumder B, Gupta SD. Formulation development and optimization of bilayer tablets of aceclofenac. Exp Op Drug Del. 2012;9(9):1041\u201350.\u00a0https:\/\/doi.org\/10.1517\/17425247.2012.707187","DOI":"10.1517\/17425247.2012.707187"},{"key":"3535_CR43","doi-asserted-by":"publisher","unstructured":"Dholariya YN, Bansod YB, Vora RM, Mittal SS, Shirsat AE, Bhingare CL. Design and optimization of bilayered tablet of Hydrochlorothiazide using the Quality-by-Design approach. Int J Pharm Investig. 2014;4(2):93\u2013101. https:\/\/doi.org\/10.4103\/2230-973x.133058","DOI":"10.4103\/2230-973x.133058"},{"key":"3535_CR44","doi-asserted-by":"publisher","unstructured":"Tak JW, Gupta B, Thapa RK, Woo KB, Kim SY, Go TG, et al. Preparation and Optimization of Immediate Release\/Sustained Release Bilayered Tablets of Loxoprofen Using Box-Behnken Design. AAPS PharmSciTech. 2017;18(4):1125\u201334.\u00a0https:\/\/doi.org\/10.1208\/s12249-016-0580-5","DOI":"10.1208\/s12249-016-0580-5"},{"key":"3535_CR45","doi-asserted-by":"publisher","unstructured":"Singh B, Saini G, Vyas M, Verma S, Thakur S. Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation. Future J Pharm Sci. 2019;5(1):5.\u00a0https:\/\/doi.org\/10.1186\/s43094-019-0006-9","DOI":"10.1186\/s43094-019-0006-9"},{"key":"3535_CR46","doi-asserted-by":"publisher","unstructured":"Maddiboyina B, Hanumanaik M, Nakkala RK, Jhawat V, Rawat P, Alam A, et al. Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. Heliyon. 2020;6(11):05459.\u00a0https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05459","DOI":"10.1016\/j.heliyon.2020.e05459"},{"key":"3535_CR47","doi-asserted-by":"publisher","unstructured":"Momin MM, Kane S, Abhang P. Formulation and evaluation of bilayer tablet for bimodal release of venlafaxine hydrochloride. Front Pharmacol. 2015;6.\u00a0https:\/\/doi.org\/10.3389\/fphar.2015.00144","DOI":"10.3389\/fphar.2015.00144"},{"key":"3535_CR48","doi-asserted-by":"publisher","unstructured":"Kurcubic I, Cvijic S, Filipcev B, Ignjatovic J, Ibric S, Djuris J. Development of propranolol hydrochloride bilayer mucoadhesive buccal tablets supported by in silico physiologically-based modeling. React Funct Polym. 2020;151:104587.\u00a0https:\/\/doi.org\/10.1016\/j.reactfunctpolym.2020.104587","DOI":"10.1016\/j.reactfunctpolym.2020.104587"},{"key":"3535_CR49","doi-asserted-by":"publisher","unstructured":"Chinta R, Pilli R. Formulation design of empaglifozin and metformin hydrochloride extended release tablets: optimization of formulation using statistical experimental design Int J Pharm Sci Res. 2020;11(12):6434\u201347. https:\/\/doi.org\/10.13040\/ijpsr.0975-8232.11(12).6434-47","DOI":"10.13040\/ijpsr.0975-8232.11(12).6434-47"},{"key":"3535_CR50","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.5958\/0974-360X.2021.00214.6","volume":"14","author":"R Chinta","year":"2021","unstructured":"Chinta R, Rohini P. Formulation development of empagliflozin and metformin hydrochloride extended release tablets: optimization of formulation using statistical experimental design. Res J Pharm Technol. 2021;14:1201\u20138. https:\/\/doi.org\/10.5958\/0974-360X.2021.00214.6.","journal-title":"Res J Pharm Technol"},{"key":"3535_CR51","doi-asserted-by":"publisher","unstructured":"Amit K, Sandeep A, Neelam S, Sukhbir S. Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach. Curr Drug Ther. 2021;16(2):184\u2013203.\u00a0https:\/\/doi.org\/10.2174\/1574885516666210315100848","DOI":"10.2174\/1574885516666210315100848"},{"key":"3535_CR52","doi-asserted-by":"publisher","unstructured":"Won DH, Park H, Ha E-S, Kim H-H, Jang SW, Kim M-S. Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). Int J Pharm. 2021;605:120838. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120838","DOI":"10.1016\/j.ijpharm.2021.120838"},{"key":"3535_CR53","doi-asserted-by":"publisher","unstructured":"Han JK, Kim JY, Choi DH, Park E-S. A formulation development strategy for dual-release bilayer tablets: An integrated approach of quality by design and a placebo layer. Int J Pharm. 2022;618:121659.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121659","DOI":"10.1016\/j.ijpharm.2022.121659"},{"key":"3535_CR54","doi-asserted-by":"publisher","unstructured":"Parmar C, Parikh K, Mundada P, Bhavsar D, Sawant K. Formulation and optimization of enteric coated bilayer tablets of mesalamine by RSM: In vitro - In vivo investigations and roentogenographic study. J Drug Del Sci Technol. 2018;44:388\u201398.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2018.01.008","DOI":"10.1016\/j.jddst.2018.01.008"},{"key":"3535_CR55","doi-asserted-by":"publisher","unstructured":"Kenjale P, Pokharkar V. Risk Assessment and QbD-Based Optimization of Sorafenib Tosylate Colon Targeted Bilayer Tablet: In Vitro Characterization, In Vivo Pharmacokinetic, and In Vivo Roentgenography Studies. AAPS Pharm Sci Tech. 2022;23(6):184.\u00a0https:\/\/doi.org\/10.1208\/s12249-022-02340-7","DOI":"10.1208\/s12249-022-02340-7"},{"key":"3535_CR56","doi-asserted-by":"publisher","unstructured":"Parmar K, Desai A. Preparation and optimization of quick\/slow-release bilayered tablets of prazosin HCl using DoE and PCA. Pharmacophore. 2022;13(2):80\u20137.\u00a0https:\/\/doi.org\/10.51847\/7Ap1qgnqwF","DOI":"10.51847\/7Ap1qgnqwF"},{"key":"3535_CR57","doi-asserted-by":"publisher","unstructured":"Sharma A, Singh S, Saini G, Sharma S, Singh B, Choudhary D. Quality by design-based development and in vitro evaluation of dual release tablet of etoricoxib and thiocolchicoside: A novel chronotherapeutic approach for arthritis pain management. Ann Pharm Fr. 2024;82(6):1103\u201317.\u00a0https:\/\/doi.org\/10.1016\/j.pharma.2024.07.004","DOI":"10.1016\/j.pharma.2024.07.004"},{"issue":"3","key":"3535_CR58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jpba.2010.04.029","volume":"53","author":"M Ito","year":"2010","unstructured":"Ito M, Suzuki T, Yada S, Nakagami H, Teramoto H, Yonemochi E, et al. Development of a method for nondestructive NIR transmittance spectroscopic analysis of acetaminophen and caffeine anhydrate in intact bilayer tablets. J Pharm Biomed Anal. 2010;53(3):396\u2013402. https:\/\/doi.org\/10.1016\/j.jpba.2010.04.029.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"3535_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010080","volume":"13","author":"JY Kim","year":"2021","unstructured":"Kim JY, Chun MH, Choi DH. Control strategy for process development of high-shear wet granulation and roller compaction to prepare a combination drug using integrated quality by design. Pharmaceutics. 2021;13(1):80. https:\/\/doi.org\/10.3390\/pharmaceutics13010080.","journal-title":"Pharmaceutics"},{"key":"3535_CR60","doi-asserted-by":"publisher","unstructured":"Mostafa M, Sayed OM, Teaima MH, El-Nabarawi MA, Yasser M. Factorial design, formulation, in vitro and in vivo evaluation of a multi-layer tablet containing ticagrelor and aspirin, for dual antiplatelet therapy. J Pharm Sci. 2025;114(7).\u00a0https:\/\/doi.org\/10.1016\/j.xphs.2025.103817","DOI":"10.1016\/j.xphs.2025.103817"},{"issue":"1-2","key":"3535_CR61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijpharm.2017.10.004","volume":"534","author":"AR Lee","year":"2017","unstructured":"Lee AR, Kwon SY, Choi DH, Park ES. Quality by design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduo (R)) manufactured via high shear wet granulation. Int J Pharm. 2017;534(1\u20132):144\u201358. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.10.004.","journal-title":"Int J Pharm"},{"issue":"3","key":"3535_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.101957","volume":"32","author":"M Akhtar","year":"2024","unstructured":"Akhtar M, Zaman M, Siddiqi AZ, Ali H, Khan R, Alvi MN, et al. Response surface methodology (RSM) approach to formulate and optimize the bilayer combination tablet of Tamsulosin and Finasteride. Saudi Pharm J. 2024;32(3):101957. https:\/\/doi.org\/10.1016\/j.jsps.2024.101957.","journal-title":"Saudi Pharm J"},{"key":"3535_CR63","unstructured":"ICH guideline Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. 2019, (2017).\u00a0https:\/\/database.ich.org\/sites\/default\/files\/Q12_Guideline_Step4_2019_1119.pdf"},{"key":"3535_CR64","unstructured":"Endorsed Guide for ICH Q8\/Q9\/Q10 Implementation. 2010.\u00a0https:\/\/database.ich.org\/sites\/default\/files\/Q8_Q9_Q10_Q%26As_R4_Points_to_Consider_0.pdf"},{"key":"3535_CR65","doi-asserted-by":"publisher","unstructured":"Zhu C, Xu S, Han X, Wang W, He W, Yin L, et al. Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs. AAPS Pharm Sci Tech. 2019;20(2):86.\u00a0https:\/\/doi.org\/10.1208\/s12249-018-1271-1","DOI":"10.1208\/s12249-018-1271-1"},{"key":"3535_CR66","doi-asserted-by":"publisher","unstructured":"Testas M, da Cunha Sais T, Medinilha LP, Niwa KNI, de Carvalho LS, Maia SD, et al. An industrial case study: QbD to accelerate time-to-market of a drug product. AAPS Open. 2021;7(1):12.\u00a0https:\/\/doi.org\/10.1186\/s41120-021-00047-w","DOI":"10.1186\/s41120-021-00047-w"},{"key":"3535_CR67","doi-asserted-by":"publisher","unstructured":"Liu T, Wang J, Feng Y, Wang H, Xu Y, Yin T, et al. Further enhancement of the sustained-release properties and stability of direct compression gel matrix bilayer tablets by controlling the particle size of HPMC and drug microencapsulation. Powder Technol. 2024;448:120256.\u00a0https:\/\/doi.org\/10.1016\/j.powtec.2024.120256","DOI":"10.1016\/j.powtec.2024.120256"},{"key":"3535_CR68","doi-asserted-by":"publisher","unstructured":"Busignies V, Mazel V, Diarra H, Tchoreloff P. Development of a new test for the easy characterization of the adhesion at the interface of bilayer tablets: Proof-of-concept study by experimental design. Int J Pharm. 2014;477(1):476\u201384.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2014.10.051","DOI":"10.1016\/j.ijpharm.2014.10.051"},{"key":"3535_CR69","doi-asserted-by":"publisher","unstructured":"Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 2016;510(1):144\u201358.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2016.05.016","DOI":"10.1016\/j.ijpharm.2016.05.016"},{"key":"3535_CR70","doi-asserted-by":"publisher","unstructured":"Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: A recent update. Asian J Pharm Sci. 2016;11(5):575\u201384.\u00a0https:\/\/doi.org\/10.1016\/j.ajps.2016.04.007","DOI":"10.1016\/j.ajps.2016.04.007"},{"key":"3535_CR71","doi-asserted-by":"publisher","unstructured":"Le TN, Her J, Sim T, Jung CE, Kang JK, Oh KT. Preparation of Gastro-retentive Tablets Employing Controlled Superporous Networks for Improved Drug Bioavailability. AAPS Pharm Sci Tech. 2020;21(8):320.\u00a0https:\/\/doi.org\/10.1208\/s12249-020-01851-5","DOI":"10.1208\/s12249-020-01851-5"},{"key":"3535_CR72","doi-asserted-by":"publisher","unstructured":"Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351\u201370.\u00a0https:\/\/doi.org\/10.1038\/s41578-020-00269-6","DOI":"10.1038\/s41578-020-00269-6"},{"key":"3535_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijpharm.2019.05.022","volume":"565","author":"Y Baranwal","year":"2019","unstructured":"Baranwal Y, Rom\u00e1n-Ospino AD, Keyvan G, Ha JM, Hong EP, Muzzio FJ, et al. Prediction of dissolution profiles by non-destructive NIR spectroscopy in bilayer tablets. Int J Pharm. 2019;565:419\u201336. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.022.","journal-title":"Int J Pharm"},{"key":"3535_CR74","doi-asserted-by":"publisher","unstructured":"Otsuka M, Fukui Y. Determination of carbamazepine polymorphic contents in double-layered tablets using transmittance- and reflectance-near-infrared spectroscopy involving chemometrics. Drug Dev Ind Pharm. 2010;36(12):1404\u201312.\u00a0https:\/\/doi.org\/10.3109\/03639045.2010.487262","DOI":"10.3109\/03639045.2010.487262"},{"issue":"3","key":"3535_CR75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1255\/jnirs.1116","volume":"22","author":"D Ishikawa","year":"2014","unstructured":"Ishikawa D, Genkawa T, Murayama K, Komiyama M, Ozaki Y. Feasibility study of diffuse reflectance and transmittance near infrared spectroscopy for rapid analysis of ascorbic acid concentration in bilayer tablets using a high-speed polychromator-type spectrometer. J Near Infrared Spectrosc. 2014;22(3):189\u201397. https:\/\/doi.org\/10.1255\/jnirs.1116.","journal-title":"J Near Infrared Spectrosc"},{"key":"3535_CR76","doi-asserted-by":"publisher","unstructured":"Be\u0305rzi\u0146\u0161 Kr, Mapley JI, Gordon KC, Fraser-Miller SJ. Evaluating Spatially Offset Low-Frequency Anti-Stokes Raman Spectroscopy (SOLFARS) for Detecting Subsurface Composition below an Emissive Layer: A Proof of Principle Study Using a Model Bilayer System. Mol Pharm. 2022;19(11):4311\u20139.\u00a0https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00656","DOI":"10.1021\/acs.molpharmaceut.2c00656"},{"key":"3535_CR77","doi-asserted-by":"publisher","unstructured":"Zhang Y, McGeorge G. Quantitative Analysis of Pharmaceutical Bilayer Tablets Using Transmission Raman Spectroscopy. J Pharm Innov. 2015;10(3):269\u201380.\u00a0https:\/\/doi.org\/10.1007\/s12247-015-9223-8","DOI":"10.1007\/s12247-015-9223-8"},{"key":"3535_CR78","doi-asserted-by":"publisher","unstructured":"Niwa M, Hiraishi Y, Iwasaki N, Terada K. Quantitative analysis of the layer separation risk in bilayer tablets using terahertz pulsed imaging. Int J Pharm. 2013;452(1):249\u201356.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2013.05.010","DOI":"10.1016\/j.ijpharm.2013.05.010"},{"key":"3535_CR79","doi-asserted-by":"publisher","unstructured":"Brands R, Fuchs L, Seyffer JM, Bajcinca N, Bartsch J, Peuker UA, et al. Penetration depth and effective sample size characterization of UV\/Vis radiation into pharmaceutical tablets. J Pharm Sci. 2025;114(12):103889.\u00a0https:\/\/doi.org\/10.1016\/j.xphs.2025.103889","DOI":"10.1016\/j.xphs.2025.103889"},{"issue":"3","key":"3535_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030330","volume":"17","author":"SH Kim","year":"2024","unstructured":"Kim SH, Han SH, Oh J-S, Seo D-W, Kang MJ. Evaluation of the ejection pressure for tracking internal cracks during compaction in bilayer tablet formulations using experimental and finite element methods. Pharmaceuticals (Basel). 2024;17(3):330. https:\/\/doi.org\/10.3390\/ph17030330.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3535_CR81","doi-asserted-by":"publisher","unstructured":"Saeed M, Probst L, Betz G. Assessment of diffuse transmission and reflection modes in near-infrared quantification, part 2: Diffuse reflection information depth. J Pharm Sci. 2011;100(3):1130\u201341.\u00a0https:\/\/doi.org\/10.1002\/jps.22344","DOI":"10.1002\/jps.22344"},{"issue":"12","key":"3535_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121659","volume":"17","author":"PJG Remoto","year":"2024","unstructured":"Remoto PJG, Gordon KC, Fraser-Miller SJ. A quantitative chemometric study of pharmaceutical tablet formulations using multi-spectroscopic fibre optic probes. Pharmaceuticals (Basel). 2024;17(12):1659. https:\/\/doi.org\/10.3390\/ph17121659.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"3535_CR83","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1248\/cpb.c18-00867","volume":"67","author":"Y Otsuka","year":"2019","unstructured":"Otsuka Y, Ito A, Takahashi T, Matsumura S, Takeuchi M, Tanaka H. Bilayer tablet dissolution kinetics based on a degassing cyclic flow UV-Vis spectroscopy with chemometrics. Chem Pharm Bull (Tokyo). 2019;67(4):361\u20136. https:\/\/doi.org\/10.1248\/cpb.c18-00867.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"3535_CR84","doi-asserted-by":"publisher","unstructured":"Hisazumi J, Watanabe T, Suzuki T, Wakiyama N, Terada K. Using Terahertz Reflectance Spectroscopy to Quantify Drug Substance in Tablets. Chem Pharm Bull. 2012;60(12):1487\u201393.\u00a0https:\/\/doi.org\/10.1248\/cpb.c12-00524","DOI":"10.1248\/cpb.c12-00524"},{"issue":"1","key":"3535_CR85","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1208\/s12249-009-9352-9","volume":"11","author":"I Akseli","year":"2010","unstructured":"Akseli I, Dey D, Cetinkaya C. Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech. 2010;11(1):90\u2013102. https:\/\/doi.org\/10.1208\/s12249-009-9352-9.","journal-title":"AAPS PharmSciTech"},{"key":"3535_CR86","unstructured":"ICH Q14 Guideline on analytical procedure development - Step 5 - Revision 1, (2022). https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q14_Guideline_2023_1116.pdf.\u00a0Accessed May 2026."},{"key":"3535_CR87","doi-asserted-by":"publisher","unstructured":"dos Santos MS, do Nascimento DD, Medeiros JJS, Louren\u00e7o FR, de Oliveira CA, Prado LD. Analytical quality by design and measurement uncertainty in the development of discriminative dissolution method for pediatric fixed-dose combination dispersible tablets of isoniazid and rifampicin. J Pharm Biomed Anal. 2025;265:116994.\u00a0https:\/\/doi.org\/10.1016\/j.jpba.2025.116994","DOI":"10.1016\/j.jpba.2025.116994"},{"key":"3535_CR88","doi-asserted-by":"publisher","unstructured":"Matta A, Sundararajan R. Analytical Quality by Design-Based Stability-Indicating Ultra-High Performance Liquid Chromatography Method for Estimation of Acoramidis Hydrochloride in Bulk and Tablet Dosage Forms. Sep Sci Plus 2025;8(9):e70116.\u00a0https:\/\/doi.org\/10.1002\/sscp.70116","DOI":"10.1002\/sscp.70116"},{"issue":"1","key":"3535_CR89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3897\/pharmacia.70.e95099","volume":"70","author":"H Kola","year":"2023","unstructured":"Kola H, Shanmugasundaram S. Analytical quality by design-based RP-HPLC method for quantification of pioglitazone and candesartan cilexetil in bilayer tablet and its forced degradation studies. Pharmacia. 2023;70(1):27\u201337. https:\/\/doi.org\/10.3897\/pharmacia.70.e95099.","journal-title":"Pharmacia"},{"key":"3535_CR90","doi-asserted-by":"publisher","unstructured":"Umapathi P, Ayyappan J, Quine S. Quantitative Determination of Metformin Hydrochloride in Tablet Formulation Containing Croscarmellose Sodium as Disintegrant by HPLC and UV Spectrophotometry. Trop J Pharm Res. 2012;11(1).\u00a0https:\/\/doi.org\/10.4314\/tjpr.v11i1.14","DOI":"10.4314\/tjpr.v11i1.14"},{"key":"3535_CR91","doi-asserted-by":"publisher","unstructured":"Phan TD, Nguyen NH, Kim DJ, Lee Y-J, Choi S-H, Kim KH. Determination of the L-enantiomer of nateglinide in pharmaceutical formulations by micellar electrokinetic chromatography. Arch Pharmacal Res. 2010;33(12):2017\u201324.\u00a0https:\/\/doi.org\/10.1007\/s12272-010-1218-x","DOI":"10.1007\/s12272-010-1218-x"},{"key":"3535_CR92","doi-asserted-by":"publisher","unstructured":"Thomas AB, Patil SD, Nanda RK, Kothapalli LP, Bhosle SS, Deshpande AD. Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form. Saudi Pharm J. 2011;19(4):221\u201331.\u00a0https:\/\/doi.org\/10.1016\/j.jsps.2011.06.005","DOI":"10.1016\/j.jsps.2011.06.005"},{"issue":"1","key":"3535_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/1752-153X-6-9","volume":"6","author":"NM El-Enany","year":"2012","unstructured":"El-Enany NM, Abdelal AA, Belal FF, Itoh YI, Nakamura MN. Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma. Chem Cent J. 2012;6(1):9. https:\/\/doi.org\/10.1186\/1752-153X-6-9.","journal-title":"Chem Cent J"},{"key":"3535_CR94","doi-asserted-by":"publisher","unstructured":"Hefnawy MM, Sultan MA, Al-Johar HI, Kassem MG, Aboul-Enein HY. Multi-objective optimization strategy based on desirability functions used for electrophoratic separation and quantification of rosiglitazone and glimepiride in plasma and formulations. Drug Test Anal. 2012;4(1):39\u201347.\u00a0https:\/\/doi.org\/10.1002\/dta.260","DOI":"10.1002\/dta.260"},{"key":"3535_CR95","doi-asserted-by":"publisher","unstructured":"Gurrala S, Raj S, CVS S, Anumolu PD. Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin. J Chromat Sci. 2021;60(1):68\u201380.\u00a0https:\/\/doi.org\/10.1093\/chromsci\/bmab030","DOI":"10.1093\/chromsci\/bmab030"},{"key":"3535_CR96","doi-asserted-by":"publisher","unstructured":"Prabhu RC, Maruthapillai A. New RP-UPLC method development using QbD approach for determination of mebendazole, quinfamide, its impurities and antioxidants in mebendazole and quinfamide fixed dose combinations (FDC). Mater Today Proc. 2021;40:S120-S6.\u00a0https:\/\/doi.org\/10.1016\/j.matpr.2020.04.243","DOI":"10.1016\/j.matpr.2020.04.243"},{"key":"3535_CR97","doi-asserted-by":"publisher","unstructured":"Patel KG, Patel AT, Shah PA, Gandhi TR. Multivariate optimization for simultaneous determination of aspirin and simvastatin by reverse phase liquid chromatographic method using AQbD approach. B-FOPCU. 2017;55(2):293\u2013301.\u00a0https:\/\/doi.org\/10.1016\/j.bfopcu.2017.08.003","DOI":"10.1016\/j.bfopcu.2017.08.003"},{"key":"3535_CR98","doi-asserted-by":"publisher","unstructured":"Dhiman S, Kurmi BD, Asati V. Analytical reversed-phase high-performance liquid chromatography method development for silodosin and solifenacin in bulk and marketed formulation using analytical quality by design approach. Sep Sci Plus. 2023;6(2):2200117.\u00a0https:\/\/doi.org\/10.1002\/sscp.202200117","DOI":"10.1002\/sscp.202200117"},{"key":"3535_CR99","doi-asserted-by":"publisher","unstructured":"Chanduluru HK, Sugumaran A. Estimation of pitavastatin and ezetimibe using UPLC by a combined approach of analytical quality by design with green analytical technique. Acta Chromatogr. 2022;34(3):361\u201372.\u00a0https:\/\/doi.org\/10.1556\/1326.2021.00949","DOI":"10.1556\/1326.2021.00949"},{"key":"3535_CR100","doi-asserted-by":"publisher","unstructured":"Sar\u0131salt\u0131k Ya\u015f\u0131n D, Arslant\u00fcrk Bing\u00fcl A, Karak\u00fc\u00e7\u00fck A, Teksin Z. Development and Validation of an HPLC Method Using an Experimental Design for Analysis of Amlodipine Besylate and Enalapril Maleate in a Fixed-dose Combination. Turk J Pharm Sci. 2021;18(3):306\u201318.\u00a0https:\/\/doi.org\/10.4274\/tjps.galenos.2020.89725","DOI":"10.4274\/tjps.galenos.2020.89725"},{"key":"3535_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac045","author":"P Prajapati","year":"2022","unstructured":"Prajapati P, Tailor P, Shahi A, Acharya A, Shah S. Application of Taguchi OA and Box-Behnken design for the implementation of DoE-based AQbD approach to HPTLC method for simultaneous estimation of azilsartan and cilnidipine. J Chromatogr Sci. 2022. https:\/\/doi.org\/10.1093\/chromsci\/bmac045.","journal-title":"J Chromatogr Sci."},{"key":"3535_CR102","unstructured":"Validation of analytical procedures Q2(R2). 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2%28R2%29_Guideline_2023_1130.pdf.\u00a0Accessed May 2026."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03535-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:39:51Z","timestamp":1794929991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":102,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03535-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to correct the formatting of Tables 2 and and to fix spacing and punctuation errors in the main text, figure captions, Author Contributions section and the references section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"264"}}